Product Description
SSGJ-706 is a recombinant bispecific antibody developed by Sanshengguojian using independent intellectual property rights bispecific antibody platform, which can bind to two targets closely related to tumor immunosuppressive function at the same time, so as to promote T cell activation and proliferation more effectively and further enhance its tumor killing activity. Its pharmacodynamic study confirmed the anti-tumor effect of SSGJ-706 in many kinds of transplanted tumors. In addition, non-clinical data suggest that SSGJ-706 is safe and tolerable. The development of SSGJ-706 is expected to enable more cancer patients to benefit from innovative immunotherapy. (Sourced from: https://www.moomoo.com/news/post/7293885/sansheng-guojian-688336-sh-bispecific-antibody-injection-ssgj-706-is?level=1&data_ticket=1723513657810351)
Mechanisms of Action: PD-1 Inhibitor,PD-L1 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sunshine Guojian Pharmaceutical (Shanghai)
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|